Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer

被引：6

作者：

Bell, R. Bryan ^{[1
]}

Gough, Michael ^{[1
]}

Crittenden, Marka ^{[1
]}

Young, Kristina ^{[1
]}

机构：

[1] Earle A Chiles Res Inst, Div Providence Canc Inst, Portland, OR USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2022年 / 132卷 / 18期

关键词：

CARCINOMA; RECURRENT; THERAPY;

D O I：

10.1172/JCI162733

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Patients with HPV-unrelated head and neck squamous cell carcinoma (HPV-unrelated HNSCC) show only modest benefit from treatment with PD-1 inhibitors (PD-1i). Targeting transforming growth factor beta (TGF-beta) may make PD-1i more effective by inducing T cell responses. In this issue of the JCI, Redman et al. performed a clinical trial in 14 patients with HPV-unrelated HNSCC using bintrafusp alfa, a bifunctional fusion protein that blocks PD-L1 and TGF-beta. Primary tumors displayed pathologic responses with 5 of 14 patients having at least a partial response. While no primary tumor or metastatic lymph node demonstrated a complete pathologic response, the findings suggest that concurrent neoadjuvant inhibition of PD-L1 and TGF-beta may provide a rational strategy to improve pathologic response and clinical outcome in patients with HPV-unrelated HNSCC.

引用

页数：5

共 26 条

[1] Targeting TGF-β Signaling for Therapeutic Gain [J].

Akhurst, Rosemary J. .

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2017, 9 (10)

[2] Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial [J].

Altorki, Nasser K. ;

McGraw, Timothy E. ;

Borczuk, Alain C. ;

Saxena, Ashish ;

Port, Jeffrey L. ;

Stiles, Brendon M. ;

Lee, Benjamin E. ;

Sanfilippo, Nicholas J. ;

Scheff, Ronald J. ;

Pua, Bradley B. ;

Gruden, James F. ;

Christos, Paul J. ;

Spinelli, Cathy ;

Gakuria, Joyce ;

Uppal, Manik ;

Binder, Bhavneet ;

Elemento, Olivier ;

Ballman, Karla, V ;

Formenti, Silvia C. .

LANCET ONCOLOGY, 2021, 22 (06) :824-835

[3] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[4] Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort [J].

Chow, Laura Q. M. ;

Haddad, Robert ;

Gupta, Shilpa ;

Mahipal, Amit ;

Mehra, Ranee ;

Tahara, Makoto ;

Berger, Raanan ;

Eder, Joseph Paul ;

Burtness, Barbara ;

Lee, Se-Hoon ;

Keam, Bhumsuk ;

Kang, Hyunseok ;

Muro, Kei ;

Weiss, Jared ;

Geva, Ravit ;

Lin, Chia-Chi ;

Chung, Hyun Cheol ;

Meister, Amy ;

Dolled-Filhart, Marisa ;

Pathiraja, Kumudu ;

Cheng, Jonathan D. ;

Seiwert, Tanguy Y. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) :3838-+

[5] Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity [J].

Crittenden, Marka R. ;

Zebertavage, Lauren ;

Kramer, Gwen ;

Bambina, Shelly ;

Friedman, David ;

Troesch, Victoria ;

Blair, Tiffany ;

Baird, Jason R. ;

Alice, Alejandro ;

Gough, Michael J. .

SCIENTIFIC REPORTS, 2018, 8

[6] PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors [J].

Duhen, Rebekka ;

Fesneau, Olivier ;

Samson, Kimberly A. ;

Frye, Alexandra K. ;

Beymer, Michael ;

Rajamanickam, Venkatesh ;

Ross, David ;

Tran, Eric ;

Bernard, Brady ;

Weinberg, Andrew D. ;

Duhen, Thomas .

JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (12)

[7] Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells [J].

Duhen, Rebekka ;

Ballesteros-Merino, Carmen ;

Frye, Alexandra K. ;

Tran, Eric ;

Rajamanickam, Venkatesh ;

Chang, Shu-Ching ;

Koguchi, Yoshinobu ;

Bifulco, Carlo B. ;

Bernard, Brady ;

Leidner, Rom S. ;

Curti, Brendan D. ;

Fox, Bernard A. ;

Urba, Walter J. ;

Bell, R. Bryan ;

Weinberg, Andrew D. .

NATURE COMMUNICATIONS, 2021, 12 (01)

[8] Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors [J].

Duhen, Thomas ;

Duhen, Rebekka ;

Montler, Ryan ;

Moses, Jake ;

Moudgil, Tarsem ;

de Miranda, Noel F. ;

Goodall, Cheri P. ;

Blair, Tiffany C. ;

Fox, Bernard A. ;

McDermott, Jason E. ;

Chang, Shu-Ching ;

Grunkemeier, Gary ;

Leidner, Rom ;

Bell, Richard Bryan ;

Weinberg, Andrew D. .

NATURE COMMUNICATIONS, 2018, 9

[9] Multiparametric immune profiling in HPV-oral squamous cell cancer [J].

Feng, Zipei ;

Bethmann, Daniel ;

Kappler, Matthias ;

Ballesteros-Merino, Carmen ;

Eckert, Alexander ;

Bell, R. Bryan ;

Cheng, Allen ;

Bui, Tuan ;

Leidner, Rom ;

Urba, Walter J. ;

Johnson, Kent ;

Hoyt, Clifford ;

Bifulco, Carlo B. ;

Bukur, Juergen ;

Wickenhauser, Claudia ;

Seliger, Barbara ;

Fox, Bernard A. .

JCI INSIGHT, 2017, 2 (14)

[10] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

← 1 2 3 →